ArticleJournal of thoracic disease2025
Impact of pre-operative inflammatory markers on overall and disease-free survival of octogenarian patients undergoing video-assisted thoracoscopic lobectomy for early-stage lung cancer: a multicenter study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of perioperative inflammatory biomarkers in patients undergoing surgical resection for non-small cell lung cancer.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The proportion of octogenarian patients who undergo surgery for lung cancer is growing over recent years. Elderly patients are characterized by age-related changes, such as inflammatory modifications of the lower respiratory tract, responsible for structural and functional alterations and tumor progression. Inflammatory markers (IMs) are a well-known prognostic factor in several tumor types, but they have not been analyzed extensively in octogenarian patients submitted to thoracoscopic lobectomy for early-stage lung cancer. The aim of our study is to assess the impact of the pre-operative IMs on the overall survival (OS), disease-free survival (DFS), and post-operative complications of this subset of patients. Methods: We conducted a retrospective and multi-institutional study. All octogenarian patients submitted to thoracoscopic lobectomy for early-stage lung cancer from January 2013 to April 2019 were enrolled. Pre-operative cellular IMs were measured in peripheral blood samples and their cut-off values were set according to previous findings in literature. Cox regression model was used to analyze the relationship between IMs, and OS and DFS. Kaplan-Meier method was used to calculate the OS and DFS rates. The follow-up period was 36 months. All P values lower than 0.05 were considered statistically significant. Results: A total of 118 patients were included. At multivariate analysis adjusted by sex, age, and chronic obstructive pulmonary disease (COPD), neutrophils-to-lymphocyte ratio (NLR) and C-reactive protein (CRP) were strongly associated with higher risk of mortality [hazard ratio (HR) 2.89, 95% confidence interval (CI): 1.05-8.02, P=0.04, HR 2.74, 95% CI: 1.15-6.52, P=0.02, respectively]. NLR >2.5 and CRP >3 were associated with worse survival (respectively P=0.02 and P=0.02). Higher levels of monocyte-to-lymphocyte ratio (MLR) were still associated with a higher mortality rate, although more weakly (P=0.056). Conclusions: Elevated pre-operative NLR and CRP can be considered as a prognostic indicator in patients with non-small cell lung cancer (NSCLC) undergoing surgery with minimally invasive approach. Post-operative course and DFS is not influenced by pre-operative IMs levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.